2025年2月5日 · Congress, the Trump administration and the courts could affect 340B policy related to contract pharmacy discounts, rebate models, payment rates and more. The 340B Drug Pricing Program, a key source of cost savings for participating hospitals, faces intensifying pressure in the early part of the new year.

2025年2月12日 · The Supreme Court’s decision, coupled with CMS’s administrative action, has led to significant contractual disputes and regulatory challenges as 340B contract hospitals seek restitution for ...

17 小时之前 · Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb...

Bristol Myers Squibb’s intended use of a rebate model, in which data validating eligibility is provided prior to receiving 340B pricing, consistent with standard business practices, would ensure 340B requirements are met and support program integrity and benefit patients by:

2025年1月15日 · In November of 2024, three lawsuits were filed by pharmaceutical manufacturers against the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA), challenging how HRSA oversees the Federal 340B Drug Pricing Program. (HRSA is the sub-agency within HHS that administers the 340B Program).

2024年5月24日 · State-level policies and activity percolating in Congress give providers reason to hope for better developments ahead. A decision issued by an appeals court represents the latest setback for 340B providers hoping to secure widespread access to …

2025年3月20日 · Trump and Biden administrations show agreement on drug costs, opposing rebate model for 340B Drug Pricing Program.

2024年12月30日 · After a long wait, HRSA issued its revised final rule pertaining to the 340B Administrative Dispute Resolute (ADR) process in mid-2024. The new ADR rule provides a defined process that can be used by covered entities and manufacturers to resolve disputes related to potential overcharges, 340B diversion, and Medicaid duplicate discounts.

Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via rebates instead of upfront discounts, despite the federal government’s position that manufacturers cannot do so without prior approval.

2025年3月17日 · The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model “was within its statutory authority,” according to a department brief filed March 17 with the United States …